Abstract: Described herein is a fusion protein comprising a bacteriophage protein fused to a cancer antigen. Vaccines are also described, as well as methods of treatment and/or prevention of cancer and methods of immunizing an individual.
Abstract: According to one embodiment, a system includes a wearable device on a head of a user and including a display in a line of vision of the user, a first detector configured to detect a movement of the user, a second detector configured to detect a state of an apparatus operated by the user, and a server connected to the wearable device, the first detector and the second detector. The server is configured to display information about work contents of the user on the display based on a detection result of the first detector and a detection result of the second detector.
Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
Type:
Application
Filed:
October 8, 2019
Publication date:
January 30, 2020
Applicants:
The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The Government of the United States, as Represented by The Secretary of The Army
Inventors:
Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
Type:
Application
Filed:
October 11, 2019
Publication date:
January 30, 2020
Inventors:
Peter M. PUSHKO, Yingyun WU, Michael J. MASSARE, Ye LIU, Gale SMITH, Bin ZHOU
Abstract: Compositions, vaccines and methods for inducing an immunity, including a protective immunity, against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more adenovirus 26 vectors using for priming immunization and an isolated HIV antigenic polypeptide in combination with one or more MVA vectors for boosting immunization induced strong protective immunity against infections by one or multiple clades of HIV.
Type:
Application
Filed:
October 4, 2019
Publication date:
January 30, 2020
Inventors:
Dan BAROUCH, Johanna SCHUITEMAKER, Maria Grazia PAU, Danielle VAN MANEN, Frank TOMAKA, Jennifer Anne HENDRIKS
Abstract: The present invention relates to a porcine parvovirus (PPV) viral protein 2 (VP2) having at amino acid position 228 a glutamic acid residue or a glutamate residue, and/or at amino acid position 414 a serine residue, and/or at amino acid position 419 a glutamine residue, and/or at amino acid position 436 a threonine residue. Further, the present invention relates to immunogenic compositions comprising said PPV viral protein 2 (VP2). Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by PPV infection in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
Type:
Application
Filed:
October 10, 2019
Publication date:
January 30, 2020
Inventors:
Scott Eugene BUCKLIN, Troy James KAISER, Jeremy KROLL, Philip UTLEY, Eric Martin VAUGHN
Abstract: The disclosure describes compositions containing PEGylated compounds using linkers, bivalent polysaccharide covalent PEG compounds, and methods of bivalent polysaccharide-PEG compounds in the development of multivalent vaccines. PEGylated conjugation of capsular polysaccharides to carrier proteins is carried out using homo-bifunctional and/or hetero-bifunctional linkers of specific lengths. Incorporation of bifunctional PEG linkers induces higher titers of functional antibodies with high avidity, eliciting higher immunologic memory, and reduced carrier protein effect. This provides immunochemically cross-reactive capsular polysaccharides wherein one or more cross-reactive capsular polysaccharides are covalently PEG compounded sequentially or concurrently to carrier protein using bifunctional linkers bearing the same or different functional groups.
Abstract: The present invention provides a composition for raising an immune response against a tumor. The composition comprises at least one tumor antigen, a saponin-based adjuvant, a TLR ligand and a Flt3 ligand.
Abstract: The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.
Abstract: The present disclosure provides methods for treating lung cancer (such as small cell lung cancer, e.g., extensive stage small cell lung cancer) in an individual. The methods comprise administering to the individual a PD-1 axis binding antagonist (such as an anti-PD-L1 antibody, e.g., atezolizumab), a platinum agent (e.g., cisplatin or carboplatin), and a topoisomerase II inhibitor (e.g., etoposide).
Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
Abstract: Provided herein are stable compositions containing anti-tau antibodies. In particular, compositions containing C2N-8E12 anti-tau antibody and a buffering system are provided herein.
Type:
Application
Filed:
June 13, 2016
Publication date:
January 30, 2020
Inventors:
Elizabeth John, Philip Verghese, Yan Hu, Matthias Kron, Katja Zipfel, Alexander Faude
Abstract: Aspects of the disclosure include compositions, devices, systems and methods for optogenetic modulation of action potentials in target cells. The subject devices include light-generating devices, control devices, and delivery devices for delivering light-responsive polypeptides, or nucleic acids encoding same, to target cells. The subject compositions and systems include light-activated polypeptides, nucleic acids comprising nucleotide sequences encoding these polypeptides, as well as expression systems that facilitate expression of these polypeptides in target cells. Also provided are methods of using the subject devices and systems to optogenetically manipulate action potentials in target cells, e.g., to treat a neurological or psychiatric condition in a human or animal subject.
Type:
Application
Filed:
October 11, 2019
Publication date:
January 30, 2020
Inventors:
Karl A. Deisseroth, Soo Yeun Lee, Charu Ramakrishnan, Andre Berndt
Abstract: This invention discloses a treatment for a patient receiving medication to treat an attention deficit disorder such as ADHD wherein the treatment results in a loss of appetite and impairment of the patient's attentiveness. The treatment combines a treatment for an attention deficit disorder with an appetite stimulant, wherein the appetite stimulant increases the caloric intake of a patient, which can increase the patient's attentiveness. The combination treatment can be given for an indefinite, including, without limitation, life-long, to allow a patient to maintain normal caloric intake during treatment for an attention deficit disorder.
Abstract: Described are solid pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, dosage units of the pharmaceutical compositions, and packages for pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, which increase stability against the degradation of the fusidic acid, and pharmaceutically acceptable salts thereof. Also described are uses of the pharmaceutical compositions and dosage units in treating diseases.
Abstract: The invention relates to pharmaceutical compositions in liquid form comprising pradofloxacin in an aqueous solution and citric acid or thioglycerol as antioxidants.
Abstract: Use of dimethyl sulfoxide (DMSO) or glycofurol or their combination as an additive in a solution comprising a solvent and at least one active ingredient selected from melatonin and/or an antioxidant metabolite, derivative or analogue thereof, for prolonging stability and/or shelf life of said at least one active ingredient in said solution by retarding a decomposition of said at least one active ingredient comprised in said solution.
Abstract: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
Type:
Application
Filed:
October 3, 2019
Publication date:
January 30, 2020
Inventors:
Jennifer Riggs-Sauthier, Stephanie Allums-Donald, Sean M. Culbertson
Abstract: A synthetic process for manufacture of a tumor-vascular targeting antitumor agent wherein the antitumor agent comprises an annexin-1 binding peptide conjugated to an anticancer drug through a linker. An efficient, practical, reproducible and scalable process for the manufacturing of a tumor-vascular targeting antitumor agent wherein the antitumor agent comprises an annexin-1 binding peptide conjugated to an anticancer drug through a linker with high purity and yield.
Abstract: A method for preparing an antibody-drug conjugate (ADC). In particular, the method mainly utilizes a combination of antibody biomolecules and an ion exchange carrier through electrostatic interaction to realize solid phase preparation of an ADC drug. Elution conditions are optimized, to control a drug-to-antibody coupling ratio (DAR) and separate a polymer-coupled drug, reduce the amount of a drug used in a coupling reaction, and enhance the targeted therapeutic effect of an ADC drug. The preparation method features fewer steps, simple operation, and programmable control, facilitating industrial scale-up production, and also realizing zero retention of reducing agents and organic solvents in the preparation process, significantly improving drug safety and reducing production costs.
Type:
Application
Filed:
March 29, 2018
Publication date:
January 30, 2020
Inventors:
Yupeng Liu, Xiaofei Zhang, Zhi Liang, Ruijun Shi, Jin Zhong, Xun Liu, Weikang Tao, Lianshan Zhang, Piaoyang Sun
Abstract: Provided herein are immunoconjugates comprising an anti-ROR1 antibody or an antigen-fragment fragment thereof and a drug moiety. These immunoconjugates are useful for treating ROR1 expressing cancers.
Type:
Application
Filed:
April 5, 2019
Publication date:
January 30, 2020
Applicant:
VelosBio Inc.
Inventors:
Brian Lannutti, Katti Jessen, Thanh-Trang Vo, Jeffry Dean Watkins
Abstract: The present invention primarily relates to a novel, flexible, modular, multi-step, targeted and conditional drug targeting and delivery system. This system bypasses some general limitations of Antibody Drug Conjugates (ADCs) and widens the applicability of these key anticancer agents in precision medicine.
Abstract: Conjugates comprise a drug or probe, a cell binding agent, and a quinone-containing linker. The quinone-containing linker may be reduced intracellularly to trigger release of the drug or probe. These conjugates may selectively deliver a drug or probe to a site of action of interest for local release of the active drug or probe.
Type:
Application
Filed:
July 26, 2019
Publication date:
January 30, 2020
Inventors:
Wenhui Zhou, Hui Wang, James J. Cali, Sarah Duellman, Jolanta Vidugiriene, Natasha Karassina
Abstract: In various embodiments deformable nano-scale vehicles (DNV) are provided that are useful for the delivery of therapeutic agents. In certain embodiments the DNVs are capable of transdermal delivery and can additionally cross the blood-brain barrier.
Type:
Application
Filed:
April 2, 2018
Publication date:
January 30, 2020
Inventors:
Varghese John, Ichiro Nishimura, Naren Subbiah, Jesus Campagna, Patricia R. Spilman, Mohammad Parvez Alam
Abstract: The present invention relates to a polynucleotide comprising a promoter comprising a human photoreceptor-specific promoter element, a core promoter and at least one transgene. Further, the invention provides a plasmid comprising the polynucleotide, a viral vector comprising the polynucleotide and a pharmaceutical composition comprising the polynucleotide. The invention also relates to the plasmid, the viral vector or the pharmaceutical composition for use as a medicament, in particular for use in the therapy of diseases of the retina.
Abstract: The invention provides compositions and methods for treating neuropathic pain. Specifically, the disclosure provides a polynucleotide comprising a trigeminal ganglion (TGG) or dorsal root ganglion (DRG) promoter operably linked to a recombinant nucleic acid encoding an endonuclease that binds to a nucleotide sequence in the human colony stimulating factor 1 (hCSF1) gene and a method of using the polynucleotide or a vector comprising the polynucleotide for treatment of neuropathic pain.
Type:
Application
Filed:
October 8, 2019
Publication date:
January 30, 2020
Inventors:
Allan Basbaum, Julia Kuhn, Zhonghui Guan
Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.
Abstract: Compositions and methods for visualizing tissue under illumination with fusion compounds of near-infrared radiation using near IR, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are provided.
Abstract: NIR active, biocompatible and multifunctional (magnetic, photo-acoustic, and photo-thermal agent) E-capped iron oxide nanoparticles for deep tissue imaging and cancer therapy, are synthesized by a simple, rapid, non-toxic, low-cost and efficient completely green synthesis technique using extract made from the leaves of a medicinal aromatic plant, Pimenta dioica.
Abstract: The present invention relates to the use of radium-223, particularly a pharmaceutically acceptable salt of radium-223, and combinations comprising radium-223, for the preparation of a medicament for the treatment or prophylaxis of a haematologic malignancy disease, particularly for the treatment of multiple myeloma thereof.
Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.
Type:
Application
Filed:
October 30, 2018
Publication date:
January 30, 2020
Inventors:
Francesco de Palo, Lorenza Fugazza, Donato Barbato, Maurizio Mariani, Daniela Chicco, Giovanni Tesoriere, Clementina Brambati
Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.
Type:
Application
Filed:
July 25, 2018
Publication date:
January 30, 2020
Inventors:
Francesco de Palo, Lorenza Fugazza, Donato Barbato, Maurizio Mariani, Daniela Chicco, Giovanni Tesoriere, Clementina Brambati
Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.
Type:
Application
Filed:
September 25, 2018
Publication date:
January 30, 2020
Inventors:
Francesco de Palo, Lorenza Fugazza, Donato Barbato, Maurizio Mariani, Daniela Chicco, Giovanni Tesoriere, Clementina Brambati
Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.
Type:
Application
Filed:
October 30, 2018
Publication date:
January 30, 2020
Inventors:
Francesco de Palo, Lorenza Fugazza, Donato Barbato, Maurizio Mariani, Daniela Chicco, Giovanni Tesoriere, Clementia Brambati
Abstract: The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and/or a label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy diagnosis and in particular for diagnosis of cancer, particularly metastatic cancer, in particular for therapy of cancer.
Type:
Application
Filed:
June 22, 2016
Publication date:
January 30, 2020
Inventors:
Magdalena Krol, Irene Benni, Paola Baiocco, Tomasz Rygiel, Alberto Boffi
Abstract: This invention relates to a method, process and apparatus for disinfecting and sterilizing all types of surfaces contaminated with microorganisms and toxic substances to render both inactive. Furthermore, this invention relates to both a method and apparatus for disinfecting and/or sterilizing breathable air and then using this air to protect a confined space from external contamination. The apparatus consists of a new ultra-violet (NUV) source that is more effective than mercury based 254 nm light for destroying DNA of virus, bacteria, spores and cists. It is most effective in breaking chemical bonds in toxic gases and Biotoxins that are useful to terrorists. It is combined with other apparatus that remove particulates and byproducts sometimes produced by the NUV source and maintains positive pressure of the confined space so as to prevent the influx of air from outside the protected zone.
Abstract: A sterilization cabinet, comprising a top panel, at least two side panels, and a floor panel forming a part of a chamber of the sterilization cabinet; at least one door connected to at least one of the at least two side panels of the sterilization cabinet; a vent formed in at least one of the two side panels; at least one first filter covering the vent and a filter cover configured to hold the first filter against the vent; a drain positioned in the floor panel, wherein the floor panel has a slope configured to cause condensate within the chamber to flow into the drain and wherein the drain is the only outlet for the condensate along the floor panel; and a second filter covering the drain such that condensate flowing into the drain passes through the second filter.
Abstract: Various implementations include a steam cabinet. The steam cabinet includes at least one chamber wall, a door, at least one heating element, at least one steam generator, a supply fan, and an exhaust fan. The at least one chamber wall defines a processing chamber. The door is for allowing access to the processing chamber. The at least one heating element is configured to provide heat to the processing chamber. The at least one steam generator is configured to provide steam to the processing chamber. The supply fan has a supply fan inlet and a supply fan outlet. The supply fan outlet is in fluid communication with the at least one heating element and the processing chamber. The exhaust fan has an exhaust fan inlet and an exhaust fan outlet. The exhaust fan inlet is in fluid communication with the processing chamber.
Type:
Application
Filed:
July 30, 2019
Publication date:
January 30, 2020
Inventors:
Stanley Weller, Lloyd L. Starks, David William Macphee, Kellis Christian Kincaid, Steven Ryley Pitts, Nicholas Corey Larsen, Jonathan George Cappola, Tim A. Haskew
Abstract: Disclosed is a bidet having a bidet seat sterilizing function. The bidet having a bidet seat sterilizing function may include: a bidet seat, disposed on the upper portion of a toilet seat, for seating a user thereon; a bidet cover for opening and closing the bidet seat; a sterilizing part which is installed on the bidet seat-facing surface of the bidet cover and sterilizes the bidet seat when the bidet cover covers the bidet seat; a driving part for driving the bidet seat and the sterilizing part; and a control part for controlling the sterilizing part and the driving part.
Type:
Application
Filed:
April 5, 2018
Publication date:
January 30, 2020
Inventors:
Keun-Hwan Kim, Man-Uk Park, Sung-Worl Jin, Doo-Youl Jeon, Da-Woon Jung, Ji-Won Han
Abstract: A light introduction device (3) has an inner cavity allowing passage of at least one of a substance introduced into a human body or a substance discharged from the human body. Light is introduced from part of an outer surface of a section, which is arranged outside the human body, of a catheter (2) as a medical conduit having a light-permeable thick portion.
Abstract: One or more aspects of the present disclosure are directed to aqueous solutions that can be used to make substrates such as an article that can inhibit or limit one or more sources of odor. In an aspect, the aqueous solution can include one or more components, where one of the components is an inhibiting agent that can function to inhibit or limit the sources of odor in an article such as a textile.
Abstract: In a system and method for disinfecting a surface of an object with iodine-laden gas, a carrier gas generation means generates a gas stream, which is then directed into a chamber that includes an iodine source. As the gas stream enters and passes through the chamber, iodine is drawn and absorbed into the gas stream, creating an iodine-laden gas that exits the chamber. In some embodiments, the iodine-laden gas then travels from the chamber and is directed into an enclosure when it interacts with microbes contained on a surface of an object housed within the enclosure or otherwise engaged by the enclosure. In other embodiments, as the iodine-laden gas exits the chamber, it is directed to a nozzle, via which the iodine-laden gas is applied to the surface of the object to be disinfected.
Abstract: A sterilization system with integrated instrument recall capabilities and related methods is disclosed. In one aspect, the sterilization system is adapted to determine a failed sterilization cycle of a sterilizer in response to failure of a biological indicator test for the sterilizer, identify sterilization cycles to be recalled based on the failed sterilization cycle, identify one or more patients for whom an item in a recalled sterilization cycle was used, and initiate a patient notification routine comprising at least one of outputting of identifying information of the one or more patients for whom an item in the recalled sterilization cycle was used and notifying the one or more patients for whom an item in the recalled sterilization cycle was used about the recalled sterilization cycle.
Abstract: Systems, devices, methods, and compositions are described for providing an actively controllable implant configured to, for example, monitor, treat, or prevent microbial growth or adherence to the implant.
Type:
Application
Filed:
August 6, 2019
Publication date:
January 30, 2020
Inventors:
Edward S. Boyden, Roy P. Diaz, Roderick A. Hyde, Jordin T. Kare, Elizabeth A. Sweeney, Lowell L. Wood, JR.
Abstract: An air purifier performing an air purifying operation by drive of an air blower, and the air purifier includes: a housing in which an inlet and outlets and are opened; an air passage that connects the inlet and the outlets and; the air blower that is disposed in the air passage; a pre-filter that is disposed so as to face the inlet; and an operation panel that has a plurality of touch keys to and a plurality of light sources which correspond to the respective touch keys, in which a human body detection unit that detects presence/absence of a person is provided in the housing, and an LED of a predetermined touch key of a first group is turned off when a person is not detected by the human body detection unit, and is turned on or blinks when a person is detected by the human body detection unit.
Abstract: A substrate includes a double-network polymer system including a cross-linked, covalently-bonded polymer and a reversible, partially ionicly-bonded polymer, wherein the substrate has a moisture level less than or equal to 15 percent of the total weight of the substrate, and wherein the substrate includes a latent retractive force. A method for manufacturing a substrate includes producing a double-network hydrogel including a cross-linked, covalently-bonded polymer and a reversible, ionicly-bonded polymer; elongating by force the double-network hydrogel in at least one direction; dehydrating while still elongated the double-network hydrogel to form a substantially-dehydrated double-network polymer system; and releasing the force to produce the substrate.
Abstract: The present invention relates to a pad for treating skin diseases, comprising agar gel and a fiber layer fixed to the inside of the gel, and a manufacturing method therefor. The pad of the present invention inhibits blood vessel exudation symptoms according to vasodilation by maintaining a low temperature of the affected area, reduces an itchy sensation and, at the same time, removes, from the skin, plasma proteins and various plasma-derived substances accumulated in skin tissue, thereby having an effect of alleviating the symptoms of the affected area.
Abstract: The present invention provides a hemostatic porous composite sponge comprising: i) a matrix of a biomaterial; and ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that said polymeric component is coated onto a surface of said matrix of a biomaterial, or said matrix is impregnated with said polymeric material, or both.
Type:
Application
Filed:
October 2, 2019
Publication date:
January 30, 2020
Inventors:
Hans Christian Hedrich, Joris Hoefinghoff
Abstract: Provided is a water absorbent resin composition which is capable of suppressing unpleasant odors, while having excellent fluidity. A water absorbent resin composition according to the present invention contains a water absorbent resin and a hydroxamic acid or a salt thereof.